X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs TORRENT PHARMA - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE TORRENT PHARMA STRIDES PHARMA SCIENCE/
TORRENT PHARMA
 
P/E (TTM) x 51.1 45.5 112.4% View Chart
P/BV x 1.1 6.2 18.0% View Chart
Dividend Yield % 0.4 0.8 52.6%  

Financials

 STRIDES PHARMA SCIENCE   TORRENT PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
TORRENT PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,550 74.0%   
Low Rs6421,144 56.1%   
Sales per share (Unadj.) Rs317.2354.7 89.4%  
Earnings per share (Unadj.) Rs7.840.1 19.6%  
Cash flow per share (Unadj.) Rs25.164.2 39.0%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.21.0 21.5%  
Book value per share (Unadj.) Rs274.3273.1 100.4%  
Shares outstanding (eoy) m89.50169.22 52.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.8 74.3%   
Avg P/E ratio x114.033.6 339.3%  
P/CF ratio (eoy) x35.721.0 170.2%  
Price / Book Value ratio x3.34.9 66.2%  
Dividend payout %25.534.9 73.0%   
Avg Mkt Cap Rs m80,058227,897 35.1%   
No. of employees `0002.514.7 17.1%   
Total wages/salary Rs m4,34111,353 38.2%   
Avg. sales/employee Rs Th11,325.84,083.0 277.4%   
Avg. wages/employee Rs Th1,731.4772.3 224.2%   
Avg. net profit/employee Rs Th280.1461.3 60.7%   
INCOME DATA
Net Sales Rs m28,39460,021 47.3%  
Other income Rs m9412,988 31.5%   
Total revenues Rs m29,33463,009 46.6%   
Gross profit Rs m3,96513,493 29.4%  
Depreciation Rs m1,5404,086 37.7%   
Interest Rs m1,9623,085 63.6%   
Profit before tax Rs m1,4039,310 15.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,529 3.8%   
Profit after tax Rs m7026,781 10.4%  
Gross profit margin %14.022.5 62.1%  
Effective tax rate %6.927.2 25.5%   
Net profit margin %2.511.3 21.9%  
BALANCE SHEET DATA
Current assets Rs m24,83652,623 47.2%   
Current liabilities Rs m18,99352,022 36.5%   
Net working cap to sales %20.61.0 2,053.4%  
Current ratio x1.31.0 129.3%  
Inventory Days Days71120 59.3%  
Debtors Days Days11376 148.8%  
Net fixed assets Rs m34,28985,016 40.3%   
Share capital Rs m895846 105.8%   
"Free" reserves Rs m23,65145,376 52.1%   
Net worth Rs m24,54646,222 53.1%   
Long term debt Rs m15,51341,115 37.7%   
Total assets Rs m65,437142,432 45.9%  
Interest coverage x1.74.0 42.7%   
Debt to equity ratio x0.60.9 71.1%  
Sales to assets ratio x0.40.4 103.0%   
Return on assets %4.16.9 58.8%  
Return on equity %2.914.7 19.5%  
Return on capital %6.914.2 48.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69714,580 107.7%   
Fx outflow Rs m7353,600 20.4%   
Net fx Rs m14,96210,980 136.3%   
CASH FLOW
From Operations Rs m1,8718,942 20.9%  
From Investments Rs m5,826-47,070 -12.4%  
From Financial Activity Rs m-10,15734,174 -29.7%  
Net Cashflow Rs m-2,615-3,655 71.5%  

Share Holding

Indian Promoters % 27.7 71.5 38.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 7.0 538.5%  
FIIs % 8.6 12.6 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.8 294.3%  
Shareholders   56,241 26,511 212.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 11, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - CADILA HEALTHCARE COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS